ACADIA PHARMACEUTICALS INC (ACAD): Results of Operations and Financial Condition
ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 acad-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results - Second quarter DAYBUE ® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID ® GAAP net
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised full-year revenue range and the specified Phase 2 topline window for remlifanserin, plus regulatory milestones (FDA Fast Track for remlifanserin and a positive EMA CHMP opinion for DAYBUE in Rett syndrome).
Market read
This is a primary earnings-and-guidance disclosure with a near-term pipeline readout window, which can drive repricing ahead of the next catalyst.
What to watch
R&D and SG&A are rising year over year, and the key pipeline catalyst is still pending; investors may discount near-term impact until topline data is released.
Background
Acadia filed an SEC 8-K with Q2 2026 results and updated 2026 GAAP financial guidance, alongside clinical and regulatory updates for its neurology portfolio.
Ticker impact
Acadia raised full-year 2026 revenue guidance to $1.24 to $1.30 billion and reiterated NUPLAZID and DAYBUE sales ranges.
Likely positive bias for ACAD into the next trading sessions, with upside skew if investors view the guidance and Phase 2 timing as de-risking.
The filing is a primary disclosure (8-K) with specific, updated numeric guidance and concrete program milestones (Fast Track, enrollment completion, topline window).
Market effects
Reinforces demand and commercial momentum for CNS and rare-disease neurology franchises, potentially supporting sentiment toward profitable specialty pharma peers.
EMA positive opinion for DAYBUE could improve European uptake expectations for neurology rare-disease treatments.
Fast Track and EU marketing authorization path highlight continued regulatory progress for neuropsychiatric indications, relevant to global CNS pharma risk appetite.
Counterpoint
The guidance raise may already reflect known commercial trends, so the market may focus on whether Phase 2 remlifanserin topline in Sep-Oct can meet high expectations.
Key entities
- issuerAcadia Pharmaceuticals Inc.
Reported Q2 2026 financial results, updated 2026 revenue guidance, and provided clinical and regulatory updates.
- productDAYBUE (trofinetide)
Q2 GAAP net sales were $125 million, up 30% YoY; EMA CHMP adopted a positive opinion for Rett syndrome marketing authorization.
- productNUPLAZID (pimavanserin)
Q2 GAAP net sales were $183 million, up 9% YoY; guidance reaffirmed at $760 to $790 million for 2026.
- clinical_programremlifanserin
Phase 2 topline results expected Sep-Oct 2026; received FDA Fast Track designation for hallucinations and delusions in Alzheimer’s disease psychosis.